Albion to fund new research into physical benefits of magnesium creatine chelate

Mineral experts Albion has announced the funding of a new clinical study to investigate the effects of its magnesium creatine chelate ingredient on physical performance.

The study, to be led by L.R. Brilla, PhD at Western Washington University in Bellingham, Washington, will compare the effects of the magnesium creatine chelate (Creatine Magna Power), the same ingredient plus whey protein stack, or placebo on physical performance.

The eight week study, planned to start before the spring season, will be done in double blind fashion, will include a three-day dietary analysis and three-day physical activity log to determine energy expenditure. The physiological attribute tests include body composition, body water, muscle strength and power.

Albion said it has plans to schedule more clinical research concerning the possible beneficial impact of its other unique mineral compounds on sports performance.

The global sports nutrition market is valued at a massive US$4.7bn, with North America ($3.2bn) and western Europe ($713.6m) dominating the podium.

Creatine, an amino acid-like compound, was first identified in 1832 for its presence in muscle. The ingredient occurs naturally in foods like fish and red meat, is classified by the International Olympic Committee as food. The amino acid creatine is available as a dietary supplement in liquid, tablet and powder forms, chiefly in the form of creatine monohydrate.